merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Compounded drugs have far less oversight than FDA-approved medications, raising safety concerns.</answer>
<question_number>2</question_number>
<answer>LillyDirect allows patients to purchase Zepbound vials directly, bypassing telehealth companies offering compounded drugs.</answer>
<question_number>3</question_number>
<answer>Compounded drugs lack FDA approval and are not controlled for safety, quality, and effectiveness.</answer>
<question_number>4</question_number>
<answer>It targets customers who cannot afford Zepbound pens, potentially reclaiming market share from compounding pharmacies.</answer>
<question_number>5</question_number>
<answer>Compounding pharmacies can legally produce tirzepatide only while it is on the FDA's shortage list.</answer>
<question_number>6</question_number>
<answer>It removes third-party supply chain entities, enabling transparent pricing and direct sales to consumers.</answer>
<question_number>7</question_number>
<answer>Medicare patients may turn to Zepbound vials since Medicare does not cover weight-loss medications.</answer>
<question_number>8</question_number>
<answer>It positions Zepbound vials as a safer, FDA-approved alternative to compounded tirzepatide.</answer>
<question_number>9</question_number>
<answer>Tirzepatide is currently on the FDA's shortage list.</answer>
<question_number>10</question_number>
<answer>Offering lower pricing to reclaim market share from compounding pharmacies.</answer>